Brief: Brainstorm Cell Therapeutics Announces Nasdaq Delisting And Transition To Otcqb
17/07/2025 23:24
Brainstorm Cell Therapeutics Inc BCLI.O: BRAINSTORM CELL THERAPEUTICS ANNOUNCES NASDAQ DELISTING AND TRANSITION TO OTCQB BRAINSTORM CELL THERAPEUTICS INC - STOCK TO BE SUSPENDED ON NASDAQ AT OPEN OF TRADING ON JULY 18, 2025 Source text: ID:nPn2c8rl3a Further company coverage: BCLI.O
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview